Antireflux Surgery in the Management of Barrett's Esophagus

Journal of Gastrointestinal Surgery

Volumn 4, Issue 2, 2000, Pages 124-128

  DeMeester, Tom R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGUS TUMOR; GASTROESOPHAGEAL REFLUX; HUMAN; REVIEW; STOMACH FUNDOPLICATION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; HUMANS;

EID: 0034152688     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(00)80046-3     Document Type: Article

References (38)

1. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-1256.
2. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus N Engl J Med 1985;313-857-859.
3. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994;89:670-680.
4. Cameron AJ, Lomboy CT. Barrett's esophagus: Age, prevalance, and extent of columnar epithelium. Gastroenterology 1992;103:1241-1245.
5. Clark GW, Ireland AP, Chandrasoma P, et al. Inflammation and metaplasia in the transitional epithelium of the gastroesophageal junction: A new marker for gastroesophageal reflux disease [abstra]. Gastroenterology 1994;106:A63.
6. Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastroesophageal junction. Lancet 1994; 344;1533-1536.
7. Oberg S, Peters JH, DeMeester TR, et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg 1997;226:522-530.
8. Oberg S, DeMeester TR, Peters JH, et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg 1999;117:572-580.
9. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998;93:1028-1032.
10. Katzka DA, Castell DD. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89:989-991.
11. Sampliner RE. Effect of up to 3 years of high-dose lansoprazol on Barrett's esophagus. Am J Gastroenterol 1994;89:1844-1848.
12. Staffer R, Francis J, Carrougher J, Kadakia S. Effect of omeprazole on Barrett's epithelium after 3 years of therapy. Gastroenterology 1996;110:A255.
13. Ortiz A, Martinez de Haro LF, Parrilla P, et al. Conservative treatment versus antireflux surgery in Barrett's esophagus: Long-term results of a prospective study. Br J Surg 1996;83: 274-278.
14. Sampliner RE, Garewal HS, Fennerty MB, Aikin M. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci 1990;35:93-96.
15. Sharma P, Morales TG, Bhattacharya A, et al. Dysplasia in short-segment Barrett's esophagus: A prospective 3-year follow up. Am J Gastroenterol 1997;92:2012-2016.
16. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.
17. Stein HJ, Kauer WKJ, Feussner H, Siewert JR. Bile reflux in benign and malignant Barrett's esophagus: Effect of medical acid suppression and Nissen fundoplication. J GASTROINTEST SURG 1998;2:333-341.
18. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med 1992;326:786-792.
19. DeMeester TR, Bonavina L, Albertucci M. Nissen fundoplication for gastroesophageal reflux disease - Evaluation of primary repair in 100 consecutive patients. Ann Surg 1986;204:9-20.
20. Stein HJ, Bremner RM, Jamieson J, DeMeester TR. Effect of Nissen fundoplication on esophageal motor function. Arch Surg 1992;127:788-791.
21. Peracchia A, Bancewicz J, Bonavina L, et al. Fundoplication is an effective treatment for gastro-oesophageal reflux disease, Gastroenterol Int 1995;8:1-7.
22. Hinder RA, Filipi CJ, Wetscher G, et al. Laparoscopic Nissen fundoplication is an effective treatment for gastroesophageal reflux disease. Ann Surg 1994;220:472-483.
23. Peters JH, DeMeester TR, Crookes P, et al. The treatment of gastroesophageal reflux disease with laparoscopic Nissen fundoplication. Ann Surg 1998;228:40-50.
24. Luostarinen M, Isolauri J, Laitmen J, et al. Fate of Nissen fundoplication after 20 years. A clinical endoscopical, and functional analysis. Gut 1993;34:1015-1020.
25. Thor KB, Silander T. A long-term randomized prospective trial of Nissen procedure versus a modified Toupet technique. Ann Surg 1989;210:719-724.
26. Johansson J, Johansson F, Joelsson B, et al. Outcome 5 years after 360 degree fundoplication for gastro-oesophageal reflux disease. Br J Surg 1993;80:46-49.
27. Wetscher G, Profanter C, Gadenstatter M, et al Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility. Langenbecks Arch Chir 1997; 382:95-99.
28. Brand DL, Ylviaakev JT, Gelfand M, Pope CE. Regression of columnar esophagus (Barrett's) epithelium after antireflux surgery. N Engl J Med 1980;302:844-848.
29. DeMeester SR, DeMeester TR. Columnar mucosa, intestinal metaplasia and adenocarcinoma of the esophagus and cardia: 50 years of controversy. Ann Surg (in press).
30. DeMeester SR, Campos GM, DeMeester TR, et al. The impact of an antireflux procedure on intestinal metaplasia of the cardia. Ann Surg 1998;228:547-556.
31. Low DS, Levine DS, Dail DH, Kozarek RA. Histology and anatomic changes in Barrett's esophagus after antireflux surgery. Am J Gastroenterol 1999;94:80-85.
32. Salo JA, Salminen JT, Kiviluoto TA, et al. Treatment of Barrett's esophagus by endoscopic laser ablation and antireflux surgery. Ann Surg 1998;227:40-44.
33. McCallum R, Polepalle S, Davenport K, et al. Role of antireflux surgery against dysplasia in Barrett's esophagus. Gastroenterology 1991;100:A121.
34. Katz D, Rothstein R, Schmed A, et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998;93: 536-541.
35. McDonald ML, Trastek VF, Allen MS, et al. Barrett's esophagus: Does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996;111:1135-1138.
36. Nigro J, Hagen J, DeMeester TR, et al. Occult esophageal adenocarcinoma: The extent of disease and implications for effective therapy. Ann Surg (in press).
37. Nigro J, Hagen JA, DeMeester TR, et al. Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: Implications for therapy. J Thorac Cardiovasc Surg 1999;117:16-23.
38. Nigro J, DeMeester SR, Hagen JA, et al. Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy. J Thorac Cardiovasc Surg 1999; 117:960-968.